Menu Search
Equities

Nova Mentis Life Science Corp

NMLSF:PKC

Nova Mentis Life Science Corp

Actions
  • Price (USD)0.011
  • Today's Change0.001 / 10.00%
  • Shares traded42.00k
  • 1 Year change-72.49%
  • Beta--
Data delayed at least 15 minutes, as of May 16 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nova Mentis Life Science Corp. is a Canadian biotechnology company. The Company is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. The Company has orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of fragile X syndrome (FXS). Its focus is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS. Its core scientific focus is on chronic neuroinflammatory conditions, which fall under three categories: neurodevelopmental, neurometabolic, and neurodegenerative. The Company operates in one segment, being research and development of psilocybin, and in one geographic area, being Canada, through its wholly owned subsidiaries, Nova Mentis Biotech Corp., and SwabAi Diagnostics Inc.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-1.22m
  • Incorporated2004
  • Employees--
  • Location
    Nova Mentis Life Science Corp700-838 West Hasting StreetVANCOUVER V6C 0A6CanadaCAN
  • Phone+1 (778) 819-0244
  • Fax+1 (778) 819-0244
  • Websitehttps://www.novamentis.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.